Methods of treating pd-l1 expressing cancer

Abstract

Described herein are methods, formulations and kits for treating a patient with cancer with nanoparticle complexes comprising a carrier protein, a binding agent and paclitaxel and optionally co-treated with an anti-PD-L1 antibody.

1 - 68 . (canceled) 
     
     
         69 . A unit-dose formulation of an anti-PD-L1 antibody which formulation comprises from about 1% to about 60% of a therapeutic dose of said antibody, wherein said formulation is packaged so as to be administered as a unit dose. 
     
     
         70 . The unit-dose formulation of  claim 69 , wherein the anti-PD-L1 antibody is atezolizumab or a biosimilar version thereof. 
     
     
         71 . The unit-dose formulation of  claim 69  which formulation comprises from about 5% to about 20% of a therapeutic dose of atezolizumab or a biosimilar version thereof. 
     
     
         72 . A kit comprising: (a) an amount of an albumin/paclitaxel/anti-PD-L1 antibody nanoparticle complexes, (b) a unit dose of a sub-therapeutic amount of anti-PD-L1 antibody, and optionally (c) instructions for use. 
     
     
         73 . The kit of  claim 72 , wherein the albumin/paclitaxel/anti-PD-L1 antibody nanoparticle complexes are lyophilized.